Analyst Ratings January 26, 2026

BofA Starts Coverage on Piper Sandler With Underperform Call; Goldman and Strong Q3 Complicate the Picture

BofA flags limited upside and lowers EPS vs. consensus as Piper Sandler posts a sizable Q3 beat and pursues Gulf expansion

By Avery Klein PIPR
BofA Starts Coverage on Piper Sandler With Underperform Call; Goldman and Strong Q3 Complicate the Picture
PIPR

BofA Securities opened coverage of Piper Sandler (NYSE:PIPR) with an Underperform rating and a $385.00 price target, citing constrained potential for outsized EPS growth versus peers tied to larger deals. The firm’s estimates sit below consensus for fiscal years 2026 and 2027, even as Piper Sandler recently posted a significant third-quarter 2025 earnings and revenue beat and received a separate upgrade from Goldman Sachs.

Key Points

  • BofA Securities initiated coverage of Piper Sandler with an Underperform rating and a $385.00 price target, citing limited scope for outsized EPS growth compared with peers.
  • Piper Sandler beat third-quarter 2025 estimates materially, reporting adjusted EPS of $3.82 (vs. $3.17 expected) and revenues of $479 million (vs. $422.8 million expected).
  • Goldman Sachs upgraded the stock to Buy, forecasting an above-average revenue CAGR of about 12.5% from 2024-2027; Piper Sandler has also completed its acquisition of Abu Dhabi-based MENA Growth Partners and announced senior leadership changes.

BofA Securities has launched coverage of Piper Sandler (NYSE:PIPR) with an Underperform recommendation and a $385.00 price target. At the time of that initiation, the stock was trading at $360.35, carrying a market capitalization of $6.37 billion and a trailing price-to-earnings ratio of 26.99.

In its analysis, BofA expressed concern that Piper Sandler lacks the runway for outsized earnings-per-share expansion relative to peer firms that participate in larger, Big Tech-driven transactions. That said, InvestingPro data shows the company’s PEG ratio stands at 0.63, which indicates the stock may trade at a modest P/E relative to near-term earnings growth projections despite the firm’s reservations.

BofA acknowledged that Piper Sandler is positioned to gain from any acceleration in merger-and-acquisition activity - notably in U.S. bank consolidation - but emphasized that the firm’s franchise is concentrated on smaller market capitalizations, particularly within the Financials and Healthcare sectors.

The research note highlights valuation and growth comparisons. Piper Sandler is priced at 21 times its 2026 estimated earnings, roughly in line with peers, yet it shows below-average EPS growth expectations: 14% for fiscal 2026 and 20% for fiscal 2027 versus peer averages of 30% and 23%, respectively. BofA’s own EPS forecasts of $17.50 for fiscal 2026 and $21.01 for fiscal 2027 sit below consensus estimates of $18.39 and $22.29. Based on this view, BofA concluded that there are more attractive risk/reward opportunities elsewhere within the investment banking coverage universe.


Those downside-leaning projections arrive amid several favorable operational developments for Piper Sandler. The company posted robust third-quarter 2025 results, reporting adjusted earnings per share of $3.82 versus a $3.17 forecast and revenues of $479 million compared with an expected $422.8 million.

Meanwhile, Goldman Sachs has taken a different stance, upgrading Piper Sandler from Neutral to Buy and projecting an above-average revenue compound annual growth rate of approximately 12.5% from 2024 through 2027.

Strategic moves by Piper Sandler include the completion of its acquisition of Abu Dhabi-based MENA Growth Partners, creating an investment banking hub in the GCC region. The firm also announced internal leadership changes: Michael Piper will assume the role of head of fixed income effective in the first quarter of 2026, and Dan Bass has been hired as managing director in the financial services investment banking group to focus on mergers and acquisitions in Texas.

These mixed signals - a conservative initiation from BofA versus strong quarterly results and a Goldman upgrade - leave investors weighing valuation, growth expectations, and franchise positioning, particularly across Financials and Healthcare subsectors and among middle-market M&A opportunities.

Risks

  • Slower-than-peer EPS growth - BofA projects below-peer EPS growth of 14% for fiscal 2026 and 20% for fiscal 2027 versus peer averages of 30% and 23%, which may constrain relative returns - impacting financials sector valuations.
  • Potential valuation disconnect - BofA’s EPS estimates ($17.50 for 2026 and $21.01 for 2027) fall short of consensus ($18.39 and $22.29), creating downside risk if consensus proves more accurate - relevant to investment banking and capital markets exposure.
  • Concentration in smaller-cap deals - Piper Sandler’s franchise skew toward smaller market capitalizations in Financials and Healthcare could limit access to the largest, higher-fee transactions enjoyed by larger peers, affecting revenue mix in its investment banking business.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026